Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical efficacy of decitabine‑containing induction chemotherapy in de novo non‑elderly acute myeloid leukemia.

International journal of oncology - 1 Jun 2020

Zheng Lu, Huang Lifang, Hui Yan, Huang Liang, Li Yi, Shang Zhen, Wei Jia, Wang Zhiqiong, Mao Xia, Wang Yin, Xiao Min, Zhang Donghua

Abstract excerpt

To improve the complete response rate (CRR) and reduce the recurrence rate of newly diagnosed non‑elderly acute myeloid leukemia (AML), the present study compared the clinical efficacy of decitabine with cytarabine (A) and daunorubicin (D)‑based remission induction therapy with D + A‑based remission induction therapy. A total of 81 patients with newly diagnosed non‑elderly AML (non‑M3) were enrolled in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cytarabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Daunorubicin

Share to Decitabine

Share to DNA Methylation

Share to Induction Chemotherapy

Share to Leukemia, Myeloid, Acute

Share to Survival Analysis

Source

Identifiers

PMID: 32236618
DOI: 10.3892/ijo.2020.5033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical efficacy of decitabine‑containing induction chemotherapy in de novo non‑elderly acute myeloid leukemia.PMID 32236618Read ↗

Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.Semantic proximity Read ↗

Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia.Semantic proximity Read ↗

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.Semantic proximity Read ↗

Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen.Semantic proximity Read ↗

Venetoclax and Azacitidine Therapy in Elder Acute Myeloid Leukemia: A Retrospective Evaluation of Real-World ExperienceSemantic proximity Read ↗

[Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].Semantic proximity Read ↗

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemiaSemantic proximity Read ↗

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid LeukemiaSemantic proximity Read ↗

Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis.Semantic proximity Read ↗

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experienceSemantic proximity Read ↗

Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation blockSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.